About this Journal Submit a Manuscript Table of Contents
Prostate Cancer
Volume 2013 (2013), Article ID 418340, 8 pages
http://dx.doi.org/10.1155/2013/418340
Review Article

The Role of Vascular Endothelial Growth Factor in Metastatic Prostate Cancer to the Skeleton

1Spinal Biology Research Laboratory, University of Melbourne, Department of Surgery, Austin Health, P.O. Box 5555, Heidelberg, VIC 3084, Australia
2Department of Spinal Surgery, Austin Health, P.O. Box 5555, Heidelberg, VIC 3084, Australia

Received 30 June 2013; Revised 4 November 2013; Accepted 14 November 2013

Academic Editor: Manfred Wirth

Copyright © 2013 Emma Roberts et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Statistics, A.B.o., 3303. 0 Causes of Death, Australia,” 2012, http://www.abs.gov.au/ausstats/abs@.nsf/Products/E0BA9CC2096C3886CA25788400127C4C?opendocument.
  2. S. C. Gupta, J. H. Kim, S. Prasad, and B. B. Aggarwal, “Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals,” Cancer and Metastasis Reviews, vol. 29, no. 3, pp. 405–434, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Pietras and A. Östman, “Hallmarks of cancer: interactions with the tumor stroma,” Experimental Cell Research, vol. 316, no. 8, pp. 1324–1331, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. I. Roato, P. D'Amelio, E. Gorassini et al., “Osteoclasts are active in bone forming metastases of prostate cancer patients,” PLoS ONE, vol. 3, no. 11, Article ID e3627, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. S. A. Meyer, H. Singh, and A. L. Jenkins, “Surgical treatment of metastatic spinal tumors,” Mount Sinai Journal of Medicine, vol. 77, no. 1, pp. 124–129, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. E. J. Brown and E. Chow, “Bone biomarkers in research and clinical practice,” in Bone Metastases, vol. 12 of Cancer Metastasis—Biology and Treatment, pp. 93–116, 2009.
  7. M. E. McGee-Lawrence and J. J. Westendorf, “Histone deacetylases in skeletal development and bone mass maintenance,” Gene, vol. 474, no. 1-2, pp. 1–11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. R. L. Clifford, K. Deacon, and A. J. Knox, “Novel regulation of vascular endothelial growth factor-A (VEGF-A) by transforming growth factor β1: requirement for Smads, β-catenin, and GSK3β,” Journal of Biological Chemistry, vol. 283, no. 51, pp. 35337–35353, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Fan, J. S. Wey, M. F. McCarty et al., “Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells,” Oncogene, vol. 24, no. 16, pp. 2647–2653, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. A. K. Olsson, A. Dimberg, J. Kreuger, et al., “VEGF receptor signalling—in control of vascular function,” Nature Reviews Molecular Cell Biology, vol. 7, no. 5, pp. 359–371, 2006.
  11. N. Ferrara, H.-P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Takahashi and M. Shibuya, “The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions,” Clinical Science, vol. 109, no. 3, pp. 227–241, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. T. L. Phung, K. Ziv, D. Dabydeen et al., “Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin,” Cancer Cell, vol. 10, no. 2, pp. 159–170, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. J. D. Hood, R. Frausto, W. B. Kiosses, M. A. Schwartz, and D. A. Cheresh, “Differential αv integrin-mediated Ras-ERK signaling during two pathways of angiogenesis,” Journal of Cell Biology, vol. 162, no. 5, pp. 933–943, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. X. Jin, J. Yin, S.-H. Kim et al., “EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction,” Cancer Research, vol. 71, no. 22, pp. 7125–7134, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. A. C. Levine, X.-H. Liu, P. D. Greenberg et al., “Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts,” Endocrinology, vol. 139, no. 11, pp. 4672–4678, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. M. W. Jackson, “A potential autocrine role for vascular endothelial growth factor in prostate cancer,” Cancer Research, vol. 62, pp. 854–859, 2002. View at Scopus
  18. X. Li, Y. Feng, J. Liu, et al., “Epigallocatechin-3-gallate inhibits IGF-I-stimulated lung cancer angiogenesis through downregulation of HIF-1alpha and VEGF expression,” Journal of Nutrigenetics and Nutrigenomics, vol. 6, no. 3, pp. 169–178, 2013.
  19. R. K. Jain, N. Safabakhsh, A. Sckell et al., “Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 18, pp. 10820–10825, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Yu, C. Ustach, and H.-R. C. Kim, “Platelet-derived growth factor signaling and human cancer,” Journal of Biochemistry and Molecular Biology, vol. 36, no. 1, pp. 49–59, 2003. View at Scopus
  21. K. Eisermann, C. J. Broderick, A. Bazarov, et al., “Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site,” Molecular Cancer, vol. 12, p. 7, 2013.
  22. T. Cohen, D. Nahari, L. W. Cerem, G. Neufeld, and B.-Z. Levin, “Interleukin 6 induces the expression of vascular endothelial growth factor,” Journal of Biological Chemistry, vol. 271, no. 2, pp. 736–741, 1996. View at Publisher · View at Google Scholar · View at Scopus
  23. Z. Von Marschall, T. Cramer, M. Höcker, G. Finkenzeller, B. Wiedenmann, and S. Rosewicz, “Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma,” Gut, vol. 48, no. 1, pp. 87–96, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Paule, S. Terry, L. Kheuang, P. Soyeux, F. Vacherot, and A. de Taille, “The NF-κB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?” World Journal of Urology, vol. 25, no. 5, pp. 477–489, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Luppi, A. M. Longo, W. I. de Boer, K. F. Rabe, and P. S. Hiemstra, “Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation,” Lung Cancer, vol. 56, no. 1, pp. 25–33, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. B. I. Terman and K. V. Stoletov, “VEGF and tumor angiogenesis,” The Einstein Quarterly Journal of Biology and Medicine, vol. 18, no. 2, 2001.
  27. S. P. Ivy, J. Y. Wick, and B. M. Kaufman, “An overview of small-molecule inhibitors of VEGFR signaling,” Nature Reviews Clinical Oncology, vol. 6, no. 10, pp. 569–579, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. P. G. Tsoutsou and M. L. Koukourakis, “Angiogenesis and bone metastasis: implications for diagnosis, prevention and treatment,” in Bone Metastases, vol. 12 of Cancer Metastasis—Biology and Treatment, pp. 51–76, 2009.
  29. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Van Der Pluijm, B. Sijmons, H. Vloedgraven, M. Deckers, S. Papapoulos, and C. Löwik, “Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases,” Journal of Bone and Mineral Research, vol. 16, no. 6, pp. 1077–1091, 2001. View at Scopus
  31. R. A. Cairns, I. S. Harris, and T. W. Mak, “Regulation of cancer cell metabolism,” Nature Reviews Cancer, vol. 11, no. 2, pp. 85–95, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. S. De, J. Chen, N. V. Narizhneva et al., “Molecular pathway for cancer metastasis to bone,” Journal of Biological Chemistry, vol. 278, no. 40, pp. 39044–39050, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Köllermann and B. Helpap, “Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue,” American Journal of Clinical Pathology, vol. 116, no. 1, pp. 115–121, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. V. J. Mandracchia, S. C. Nelson, and E. A. Barp, “Current concepts of bone healing,” Clinics in Podiatric Medicine and Surgery, vol. 18, no. 1, pp. 55–77, 2001. View at Scopus
  35. B. F. Boyce, E. Rosenberg, A. E. de Papp, et al., “The osteoclast, bone remodelling and treatment of metabolic bone disease,” European Journal of Clinical Investigation, vol. 42, no. 12, pp. 1332–1341, 2012.
  36. J. Street and B. Lenehan, “Vascular endothelial growth factor regulates osteoblast survival—evidence for an autocrine feedback mechanism,” Journal of Orthopaedic Surgery and Research, vol. 4, no. 1, article 19, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. R. A. D. Carano and E. H. Filvaroff, “Angiogenesis and bone repair,” Drug Discovery Today, vol. 8, no. 21, pp. 980–989, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. H.-P. Gerber, K. J. Hillan, A. M. Ryan et al., “VEGF is required for growth and survival in neonatal mice,” Development, vol. 126, no. 6, pp. 1149–1159, 1999. View at Scopus
  39. H.-P. Gerber, V. Dixit, and N. Ferrara, “Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells,” Journal of Biological Chemistry, vol. 273, no. 21, pp. 13313–13316, 1998. View at Publisher · View at Google Scholar · View at Scopus
  40. H.-P. Gerber, T. H. Vu, A. M. Ryan, J. Kowalski, Z. Werb, and N. Ferrara, “VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation,” Nature Medicine, vol. 5, no. 6, pp. 623–628, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Z. Eghbali-Fatourechi, J. Lamsam, D. Fraser, D. Nagel, B. L. Riggs, and S. Khosla, “Circulating osteoblast-lineage cells in humans,” The New England Journal of Medicine, vol. 352, no. 19, pp. 1959–1966, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. E. F. Eriksen, “Cellular mechanisms of bone remodeling,” Reviews in Endocrine and Metabolic Disorders, vol. 11, no. 4, pp. 219–227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Kassem, L. Risteli, L. Mosekilde, F. Melsen, and E. F. Eriksen, “Formation of osteoblast-like cells from human mononuclear bone marrow cultures,” Acta Pathologica, Microbiologica et Immunologica Scandinavica, vol. 99, no. 3, pp. 269–274, 1991. View at Scopus
  44. J.-K. Jin, F. Dayyani, and G. E. Gallick, “Steps in prostate cancer progression that lead to bone metastasis,” International Journal of Cancer, vol. 128, no. 11, pp. 2545–2561, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. K. N. Weilbaecher, T. A. Guise, and L. K. McCauley, “Cancer to bone: a fatal attraction,” Nature Reviews Cancer, vol. 11, no. 6, pp. 411–425, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Cossigny and G. M. Y. Quan, “In vivo animal models of spinal metastasis,” Cancer and Metastasis Reviews, vol. 31, no. 1, pp. 99–108, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Curtin, H. Youm, and E. Salih, “Three-dimensional cancer-bone metastasis model using ex-vivo co-cultures of live calvarial bones and cancer cells,” Biomaterials, vol. 33, no. 4, pp. 1065–1078, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Sonpavde and C. N. Sternberg, “Satraplatin for the therapy of castration-resistant prostate cancer,” Future Oncology, vol. 5, no. 7, pp. 931–940, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. B. Psaila and D. Lyden, “The metastatic niche: adapting the foreign soil,” Nature Reviews Cancer, vol. 9, no. 4, pp. 285–293, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Zhang, M. Soori, F. L. Miles et al., “Paracrine factors produced by bone marrow stromal cells induce apoptosis and neuroendocrine differentiation in prostate cancer cells,” Prostate, vol. 71, no. 2, pp. 157–167, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. R. R. Langley and I. J. Fidler, “The seed and soil hypothesis revisited—the role of tumor-stroma interactions in metastasis to different organs,” International Journal of Cancer, vol. 128, no. 11, pp. 2527–2535, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. J. A. Sterling, J. R. Edwards, T. J. Martin, and G. R. Mundy, “Advances in the biology of bone metastasis: how the skeleton affects tumor behavior,” Bone, vol. 48, no. 1, pp. 6–15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Chen, S. De, J. Brainard, and T. V. Byzova, “Metastatic properties of prostate cancer cells are controlled by VEGF,” Cell Communication and Adhesion, vol. 11, no. 1, pp. 1–11, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. M. P. Yavropoulou, A. H. van Lierop, N. A. Hamdy, et al., “Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover,” Bone, vol. 51, no. 1, pp. 153–157, 2012.
  55. D. Diarra, M. Stolina, K. Polzer et al., “Dickkopf-1 is a master regulator of joint remodeling,” Nature Medicine, vol. 13, no. 2, pp. 156–163, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. J. L. Sottnik, C. L. Hall, J. Zhang, et al., “Wnt and Wnt inhibitors in bone metastasis,” BoneKEy Reports, vol. 1, p. 101, 2012.
  57. S. M. Tu, A. Som, B. Tu, et al., “Effect of Paget's disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis,” British Journal of Cancer, vol. 107, no. 4, pp. 646–651, 2012.
  58. Y. Li, D. Kong, A. Ahmad, B. Bao, and F. H. Sarkar, “Targeting bone remodeling by isoflavone and 3,3′-diindolylmethane in the context of prostate cancer bone metastasis,” PLoS ONE, vol. 7, no. 3, Article ID e33011, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. D. L. Lacey, W. J. Boyle, W. S. Simonet et al., “Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab,” Nature Reviews Drug Discovery, vol. 11, no. 5, pp. 401–419, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. L. Mercatali, M. Ricci, E. Scarpi, et al., “RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study,” International Journal of Molecular Sciences, vol. 14, no. 6, pp. 10683–10693, 2013.
  61. T. A. Guise, K. S. Mohammad, G. Clines, et al., “Basic mechanisms responsible for osteolytic and osteoblastic bone metastases,” Clinical Cancer Research, vol. 12, no. 20, pp. 6213s–6216s, 2006.
  62. J. L. F. Duque, K. R. Loughlin, R. M. Adam, P. W. Kantoff, D. Zurakowski, and M. R. Freeman, “Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer,” Urology, vol. 54, no. 3, pp. 523–527, 1999. View at Publisher · View at Google Scholar · View at Scopus
  63. P. J. Saylor, K. R. Kozak, M. R. Smith et al., “Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer,” Oncologist, vol. 17, no. 2, pp. 212–219, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. F. Botelho, F. Pina, P. Silva, G. Figueiredo, F. Cruz, and N. Lunet, “Vascular endothelial growth factor (VEGF) and prostate pathology,” International Brazilian Journal of Urology, vol. 36, no. 4, pp. 430–438, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. E. K. Amankwah, T. A. Sellers, and J. Y. Park, “Gene variants in the angiogenesis pathway and prostate cancer,” Carcinogenesis, vol. 33, no. 7, pp. 1259–1269, 2012.
  66. M. Borre, S. M. Bentzen, B. Nerstrøm, and J. Overgaard, “Tumor cell proliferation and survival in patients with prostate cancer followed expectantly,” Journal of Urology, vol. 159, no. 5, pp. 1609–1614, 1998. View at Scopus
  67. T. T. Tomiá, H. Gustavsson, W. Wang, K. Jennbacken, K. Welén, and J.-E. Damber, “Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2,” Prostate, vol. 72, no. 7, pp. 705–712, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. N. K. Thudi, C. K. Martin, M. V. P. Nadella et al., “Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions,” Prostate, vol. 68, no. 10, pp. 1116–1125, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. G. Ligresti, A. C. Aplin, P. Zorzi, A. Morishita, and R. F. Nicosia, “Macrophage-derived tumor necrosis factor-α is an early component of the molecular cascade leading to angiogenesis in response to aortic injury,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 5, pp. 1151–1159, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. C. Fischbach, J. K. Hyun, S. X. Hsiong, M. B. Evangelista, W. Yuen, and D. J. Mooney, “Cancer cell angiogenic capability is regulated by 3D culture and integrin engagement,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 2, pp. 399–404, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. V. Ouellet and P. M. Siegel, “CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis,” Journal of Cell Communication and Signaling, vol. 6, no. 2, pp. 73–85, 2012.
  72. Y. Takei, K. Kadomatsu, Y. Yuzawa, S. Matsuo, and T. Muramatsu, “A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics,” Cancer Research, vol. 64, no. 10, pp. 3365–3370, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Srinivasan, R. Kumar, S. Koduru, A. Chandramouli, and C. Damodaran, “Inhibiting TNF-mediated signaling: a novel therapeutic paradigm for androgen independent prostate cancer,” Apoptosis, vol. 15, no. 2, pp. 153–161, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. E. Corey, “Androgen suppression: the good, the bad and the ugly,” Andrology, vol. 1, Article ID e106, 2012. View at Publisher · View at Google Scholar
  75. L. Pan, S. Baek, P. R. Edmonds, et al., “Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610,” Radiation Oncology, vol. 8, article 100, 2013.
  76. L. Yang, S. You, V. Kumar, et al., “In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line,” Journal of Experimental & Clinical Cancer Research, vol. 31, article 40, 2012.
  77. T. Brabletz, D. Lyden, P. S. Steeg, et al., “Roadblocks to translational advances on metastasis research,” Nature Medicine, vol. 19, no. 9, pp. 1104–1109, 2013.
  78. N. Kamiya, H. Suzuki, T. Endo et al., “Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade,” International Journal of Urology, vol. 19, no. 2, pp. 169–173, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. A. F. Dawood, P. Lotfi, S. N. Dash, S. K. Kona, K. T. Nguyen, and M. I. Romero-Ortega, “VEGF release in multiluminal hydrogels directs angiogenesis from adult vasculature in vitro,” Cardiovascular Engineering and Technology, vol. 2, no. 3, pp. 173–185, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. V. T. Labropoulou, A. D. Theocharis, A. Symeonidis, S. S. Skandalis, N. K. Karamanos, and H. P. Kalofonos, “Pathophysiology and pharmacological targeting of tumor-induced bone disease: current status and emerging therapeutic interventions,” Current Medicinal Chemistry, vol. 18, no. 11, pp. 1584–1598, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. K. N. Syrigos, E. Karapanagiotou, P. Boura, C. Manegold, and K. Harrington, “Bevacizumab-induced hypertension: pathogenesis and management,” BioDrugs, vol. 25, no. 3, pp. 159–169, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. P. Twardowski, W. M. Stadler, P. Frankel, et al., “Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer: a California cancer consortium trial,” Urology, vol. 76, pp. 923–926, 2010. View at Scopus
  83. S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet, and M. Lynch, “Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling,” Molecular Cancer Therapeutics, vol. 7, no. 10, pp. 3129–3140, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Grothey and E. Galanis, “Targeting angiogenesis: progress with anti-VEGF treatment with large molecules,” Nature Reviews Clinical Oncology, vol. 6, no. 9, pp. 507–518, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. A. O'Donnell, A. Padhani, C. Hayes et al., “A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points,” British Journal of Cancer, vol. 93, no. 8, pp. 876–883, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Narayana, D. Gruber, S. Kunnakkat et al., “A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma: clinical article,” Journal of Neurosurgery, vol. 116, no. 2, pp. 341–345, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. H. I. Hurwitz, N. C. Tebbutt, F. Kabbinavar, et al., “Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials,” Oncologist, vol. 18, no. 9, pp. 1004–1012, 2013.
  88. M. Furuse, N. Nonoguchi, S. Kawabata, et al., “Bevacizumab treatment for symptomatic radiation necrosis diagnosed by amino acid PET,” Japanese Journal of Clinical Oncology, vol. 43, no. 3, pp. 337–341, 2013.